(813) 971-8080

7210 Wareham Drive, Tampa, FL 33647

weight loss market

Weight Loss Market’s Leaders Lost At Least $971 Million in 2023

Sept. 24, 2024 Marketdata LLC, DietBusinessWatch.com’s parent), estimates that the top competitors in the U.S. weight loss market lost at least $971 million in revenues last year, due to the juggernaut of GLP-1 medications. This is a huge transfer of sales from commercial and retail weight loss programs and product segments to medical programs. Here’s

Weight Loss Market’s Leaders Lost At Least $971 Million in 2023 Read More »

GLP-1 Drugs Market Update

Sept. 23, 2024 According to Becker’s Hospital Review… On Sept. 24, Novo Nordisk CEO Lars Fruergaard Jørgensen is slated to testify at a Senate committee hearing about the costs for Wegovy and Ozempic.  The hearing comes after months of disagreements between Denmark-based Novo Nordisk and the Senate Committee on Health, Education, Labor and Pensions. The

GLP-1 Drugs Market Update Read More »

Study finds that 42% of online pharmacies selling semaglutide are illegal

August 14, 2024 Nearly half of online pharmacies that sell semaglutide — the active ingredient in Ozempic and Wegovy — are doing so illegally, posing safety risks for consumers, according to a study published Aug. 2 in JAMA Network Open.  Of the 317 online pharmacies included in the study, researchers found 42.27% were operating illegally, meaning

Study finds that 42% of online pharmacies selling semaglutide are illegal Read More »

Medifast Reports Q2 Results

August 5, 2024 Wellness company Medifast (NYSE:MED) fell short of analysts’ expectations. Management said that: “We are acting decisively to transform our business to position us for long-term growth, with a strong balance sheet free of debt, a clear focus on new customer acquisition, and a broader health and wellness offer to a significantly expanded

Medifast Reports Q2 Results Read More »

Scroll to Top